ELOCON

Krajina: Indonézia

Jazyk: indonézština

Zdroj: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

Aktívna zložka:

MOMETASONE FUROATE

Dostupné z:

ORGANON PHARMA INDONESIA TBK - Indonesia

INN (Medzinárodný Name):

MOMETASONE FUROATE

Dávkovanie:

1,00 MG

Forma lieku:

SALEP

Počet v balení:

DUS, TUBE @ 10 G

Výrobca:

ORGANON PHARMA INDONESIA TBK - Indonesia

Dátum Autorizácia:

2021-08-05

Súhrn charakteristických

ELOCON

MOMETASONE FUROATE
Cream, Lotion and Ointment
COMPOSITION:
Each gram of ELOCON

Cream 0.1% contains 1 mg mometasone furoate
Each gram of ELOCON

Lotion 0.1% contains 1 mg mometasone furoate
Each gram of ELOCON

Ointment 0.1% contains 1 mg mometasone furoate
ACTIONS:
Mometasone
furoate,
a
synthetic
corticosteroid,
exhibits
anti-inflammatory, antipruritic
and
vasoconstrictive properties.
INDICATIONS AND USAGE:
ELOCON

Cream, Ointment and Lotion 0.1% are indicated for the relief of the
inflammatory and
pruritic manifestations of corticosteroid responsive dermatoses, such
as psoriasis and atopic
dermatitis.
DOSAGE AND ADMINISTRATION:
A thin film of ELOCON

Cream or Ointment 0.1% should be applied to the affected skin areas
once
daily. Do not use occlusive dressing.
Apply a few drops of ELOCON

Lotion to affected skin once daily; massage gently and thoroughly
until the medication disappears.
ADVERSE REACTIONS:
Local adverse reactions reported very rarely with ELOCON

Cream 0.1% include paresthesia, pruritus
and signs of skin atrophy.
Local adverse reactions rarely reported with ELOCON

Lotion 0.1% include burning, folliculitis,
acneiform reaction, pruritus and signs of skin atrophy.
DISETUJUI OLEH BPOM : 02/07/2021
ID : EREG100373VR12100277
Local adverse reactions rarely reported with ELOCON

Ointment 0.1% include burning, pruritus,
tingling / stinging and signs of skin atrophy.
The following local adverse reactions have been reported infrequently
with the use of other topical
corticosteroids:
Burning,
pruritus,
irritation,
dry
skin,
folliculitis,
hypertrichosis,
acneiform
eruption,
hypopigmentation,
perioral
dermatitis,
allergic
contact
dermatitis,
maceration
of
the
skin,
secondary infection, skin atrophy, striae and miliaria.
Systemic adverse reactions, such as vision blurred, have also been
reported with the use of topical
corticosteroids.
PRECAUTIONS:
If irritation or sensitization develops with the use of ELOCON

products, treatment should be
discontinued and appropriate t